<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/6C3712F6-BDFA-4D7B-9770-ABAEA9E72214"><gtr:id>6C3712F6-BDFA-4D7B-9770-ABAEA9E72214</gtr:id><gtr:name>Novozymes Biopharma UK Ltd</gtr:name><gtr:address><gtr:line1>Castle court</gtr:line1><gtr:line2>59 Castle Boulevard</gtr:line2><gtr:line4>Nottingham</gtr:line4><gtr:postCode>NG7 1FD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Chemistry</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/6C3712F6-BDFA-4D7B-9770-ABAEA9E72214"><gtr:id>6C3712F6-BDFA-4D7B-9770-ABAEA9E72214</gtr:id><gtr:name>Novozymes Biopharma UK Ltd</gtr:name><gtr:address><gtr:line1>Castle court</gtr:line1><gtr:line2>59 Castle Boulevard</gtr:line2><gtr:line4>Nottingham</gtr:line4><gtr:postCode>NG7 1FD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/95FF468F-3A7C-4D7C-9442-BCDD940A5AE4"><gtr:id>95FF468F-3A7C-4D7C-9442-BCDD940A5AE4</gtr:id><gtr:firstName>Stephen</gtr:firstName><gtr:surname>Caddick</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/A0E55D4C-8E28-4B81-89B3-A3B08401A438"><gtr:id>A0E55D4C-8E28-4B81-89B3-A3B08401A438</gtr:id><gtr:firstName>James</gtr:firstName><gtr:otherNames>Richard</gtr:otherNames><gtr:surname>Baker</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/29F35B45-0BF2-4F52-905E-552188EC64A7"><gtr:id>29F35B45-0BF2-4F52-905E-552188EC64A7</gtr:id><gtr:firstName>Kerry</gtr:firstName><gtr:otherNames>Ann</gtr:otherNames><gtr:surname>Chester</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=BB%2FL024349%2F1"><gtr:id>95044788-F4D7-412A-B00C-81226F0871D6</gtr:id><gtr:title>A Chemical Technology to Generate Homogeneous Antibody-Drug-Conjugates (ADCs) and Bispecifics</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>BB/L024349/1</gtr:grantReference><gtr:abstractText>Using antibodies as therapeutics and diagnostics is one of the most promising areas of research into new healthcare products. Antibodies represent the fastest growing class of therapeutics, with over 20 approved for clinical use to date and over 150 in clinical development. It is estimated that the global market for antibody therapeutics is currently around $50 billion. Two particularly promising classes of antibody based therapeutics are antibody-drug-conjugates (ADCs) and bispecifics, commonly referred to as 'magic-bullet' therapies due to their ability to seek and destroy just diseased cells within the body (e.g. cancer cells). However, a major hindrance to the area is the lack of suitable chemical methods for the construction of homogeneous, well defined, antibody conjugates. Here we propose to exemplify a powerful new chemical technology that we have developed to overcome these limitations, to enable the design of superior next generation ADCs and bispecifics.</gtr:abstractText><gtr:fund><gtr:end>2017-01-30</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2014-07-31</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>480085</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Novozymes Biopharma UK ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Collaboration with Novozymes</gtr:description><gtr:id>939AD4FF-2BBC-4AE5-ABA8-40002E058336</gtr:id><gtr:impact>N/A</gtr:impact><gtr:partnerContribution>Novozymes are providing funds (contractually confidential) and are also carrying out proof of concept experiments as part of the collaboration.</gtr:partnerContribution><gtr:piContribution>Option and evaluation agreement signed between Novozymes and UCL Business to exploit our protein conjugation technology for the development of albumin conjugates for therapy. Our role is to provide the expertise on the use of next generation maleimides for protein conjugation.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>Our reagents for protein modification are being used by Albumedix as part of a platform technology for the half-life extension of therapeutics. Available for clients of Albumedix to use in future therapeutic developments.
Our antibody drug conjugate platform is also being evaluated by 2 other companies currently (confidential).</gtr:description><gtr:firstYearOfImpact>2016</gtr:firstYearOfImpact><gtr:id>E6872FE1-FD8E-4E05-98D3-A45DC4AC5283</gtr:id><gtr:impactTypes><gtr:impactType>Economic</gtr:impactType></gtr:impactTypes><gtr:sector>Chemicals,Healthcare,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Licensed technology for use on serum stabilisation of drugs, by conjugation to albumin. Albumedix (previously Nozozymes) are licensees.</gtr:description><gtr:id>5C6A7FAA-A80A-4D6E-805D-7B853082C024</gtr:id><gtr:impact>Ongoing evaluations with other companies in biopharmaceutical area.</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:patentId>WO/2011/018611</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Licensed technology</gtr:title><gtr:yearProtectionGranted>2015</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:keyFindingsOutput><gtr:description>In this project we optimized a new approach to the synthesis of antibody-drug conjugates (ADCs), which represent the archetypal 'magic-bullet' therapies for cancer therapy. We showed that using our proprietary 'Next Generation Maleimide' reagents we could produce ADCs of extremely high homogeneity, stability and efficacy. Our approach is now being increasingly cited in the literature as a leading method for the construction of next generation ADCs.</gtr:description><gtr:exploitationPathways>Ultimately a new chemical platform for the construction of ADCs and bispecifics will allow the efficient generation of improved classes of therapeutics and diagnostics.</gtr:exploitationPathways><gtr:id>83E95737-9B71-48EA-A24C-EE8E4B8D1AC1</gtr:id><gtr:sectors><gtr:sector>Chemicals,Healthcare,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>Thiologics</gtr:companyName><gtr:description>In 2011 Dr James Baker co-founded Thiologics (www.thiologics.com), to provide a vehicle to translate the Next Generation Maleimide platform for homogeneous protein conjugation towards clinical product development. ThioLogics is a company formed by UCL Business (UCLB) and is in an early pre-seed phase of development supported solely by UCLB funds. The formation of ThioLogics has created a market presence and facilitated early engagement through our existing networks.</gtr:description><gtr:id>E641695A-DBA2-4EB4-870F-F85049C1602F</gtr:id><gtr:impact>N/A</gtr:impact><gtr:url>http://www.thiologics.com/</gtr:url><gtr:yearCompanyFormed>2011</gtr:yearCompanyFormed></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BEE9D049-5146-4741-8ADA-132308E6BE5A"><gtr:id>BEE9D049-5146-4741-8ADA-132308E6BE5A</gtr:id><gtr:title>A platform for efficient, thiol-stable conjugation to albumin's native single accessible cysteine.</gtr:title><gtr:parentPublicationTitle>Organic &amp; biomolecular chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b77bc6a4e32db0241e6065e5b24f68bc"><gtr:id>b77bc6a4e32db0241e6065e5b24f68bc</gtr:id><gtr:otherNames>Smith ME</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1477-0520</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/86090D6A-6C9F-437C-AE6F-BD2319D5C3A7"><gtr:id>86090D6A-6C9F-437C-AE6F-BD2319D5C3A7</gtr:id><gtr:title>Functional native disulfide bridging enables delivery of a potent, stable and targeted antibody-drug conjugate (ADC).</gtr:title><gtr:parentPublicationTitle>Chemical communications (Cambridge, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/53ad80b0f6f78f1f483527d5a3124bb1"><gtr:id>53ad80b0f6f78f1f483527d5a3124bb1</gtr:id><gtr:otherNames>Nunes JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1359-7345</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A2E44BD5-F8FC-47EF-B44F-5D11744EDF89"><gtr:id>A2E44BD5-F8FC-47EF-B44F-5D11744EDF89</gtr:id><gtr:title>Pyridazinediones deliver potent, stable, targeted and efficacious antibody-drug conjugates (ADCs) with a controlled loading of 4 drugs per antibody</gtr:title><gtr:parentPublicationTitle>RSC Adv.</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/fe29cc661306d654b9abacc95dc33bae"><gtr:id>fe29cc661306d654b9abacc95dc33bae</gtr:id><gtr:otherNames>Robinson E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">BB/L024349/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>